Last reviewed · How we verify
ceftriaxone plus metronidazole
At a glance
| Generic name | ceftriaxone plus metronidazole |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients (PHASE3)
- Povidone Iodine Versus Normal Saline in Preoperative Vaginal Cleansing Before Caesarean Section (NA)
- Risk Factors of Failure of Conservative Treatment in Acute Non Complicated Appendicitis
- Effects of Probiotic in Treatment of Persistent Diarrhea in Children (NA)
- A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor (PHASE3)
- Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth (PHASE4)
- Non-operative vs. Operative Management of Acute Appendicitis in Vulnerable Patient Populations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: